Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
[A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia].
A prospect i ve r and omized controlled study was performed to compare the clinical effects of naftopidil and tamsulosin .  Men complaining of lower urinary tract symptoms due to benign prostatic hyperplasia were r and omized into two groups : one receiving 50 mg naftopidil once daily ( Naf group , n=36 patients ) , and the other receiving 0.2 mg tamsulosin once daily ( Tam group , n=32 patients ) . In the Naf group at 12 weeks , 7 items of the International Prostate Symptom Score ( IPSS ) , storage and voiding symptoms , total IPSS , quality of life ( QOL ) index ( QOLI ) and Qmax were improved significantly . In the Tam group at 12 weeks , 6 items of IPSS except urgency , storage and voiding symptoms , total IPSS , QOLI and Qmax were improved significantly . Improvement of residual urine volume ( PVR ) was insignificant in both groups . In intergroup comparison between the Naf and the Tam groups , variations of 7 items of IPSS , storage and voiding symptoms , total IPSS , QOLI , Qmax and PVR at 4 and 12 weeks after treatment were not statistically significant . There was almost no difference in clinical efficacy between Naf and Tam
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .